US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Provident

20.93

+0.09000.43%

Post-market: 20.930.00000.00%17:38 EST

Volume:949.22K

Turnover:19.85M

Market Cap:2.73B

PE:10.67

High:21.16

Open:20.80

Low:20.57

Close:20.84

52wk High:21.29

52wk Low:14.34

Shares:130.62M

Float Shares:126.13M

Volume Ratio:0.75

T/O Rate:0.75%

Dividend:0.96

Dividend Rate:4.59%

EPS(TTM):1.96

EPS(LYR):1.05

ROE:9.51%

ROA:1.05%

PB:0.99

PE(LYR):19.87

Loading ...

Overview Company News Filings

3 Dividend Stocks To Enhance Your Portfolio

Simply Wall St.

Provident Financial Services Inc. Appoints New Executives and Promotes Key Leaders

Press Release: Provident Bank Announces New Hires and Promotions

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns

FDA Approves Enhertu Combination Therapy for First-Line HER2-Positive Breast Cancer Treatment

Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative?

Simply Wall St.

Dividend Stocks To Consider In December 2025

Simply Wall St.

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

High-Grade Sandstone Hub Drilling And PFS Progress Could Be A Game Changer For Brightstar Resources (ASX:BTR)

Simply Wall St.

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Why Is Arcellx Stock Surging Today?

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":20.93,"timestamp":1766005200000,"preClose":20.84,"halted":0,"volume":949220,"hourTrading":{"tag":"盘后","latestPrice":20.93,"preClose":20.93,"latestTime":"17:38 EST","volume":83723,"amount":1752322.39,"timestamp":1766011081158},"delay":0,"floatShares":126131374,"shares":130622384,"eps":1.961165,"marketStatus":"Post-Mkt","change":0.09,"latestTime":"12-17 17:49:41 EST","open":20.8,"high":21.155,"low":20.57,"amount":19850271.83946,"amplitude":0.028071,"askPrice":23.12,"askSize":100,"bidPrice":20.53,"bidSize":97,"shortable":3,"etf":0,"ttmEps":1.961165,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766019600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":20.84,"dividendRate":0.045867,"preHourTrading":{"tag":"盘前","latestPrice":20.85,"preClose":20.84,"latestTime":"09:28 EST","volume":1980,"amount":40992.690420000006,"timestamp":1765981695148},"postHourTrading":{"tag":"盘后","latestPrice":20.93,"preClose":20.93,"latestTime":"17:38 EST","volume":83723,"amount":1752322.39,"timestamp":1766011081158},"volumeRatio":0.752781,"impliedVol":0.7865,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126131374,"roa":"1.05%","roe":"9.51%","lyrEps":1.053397,"volumeRatio":0.752781,"shares":130622384,"dividePrice":0.96,"high":21.155,"amplitude":0.028071,"preClose":20.84,"low":20.57,"week52Low":14.335,"pbRate":"0.99","psRate":"3.27","week52High":21.29,"institutionHeld":0.7084,"latestPrice":20.93,"committee":-0.015228,"eps":1.961165,"divideRate":0.045867,"volume":949220,"delay":0,"ttmEps":1.961165,"open":20.8,"prevYearClose":18.87,"prevWeekClose":21.02,"prevMonthClose":19.18,"prevQuarterClose":19.28,"fiveDayClose":20.68,"twentyDayClose":18.01,"sixtyDayClose":19.63,"dividendPayoutRate":0.9113373210669862,"dividendFrequency":"Q","dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.04766441312238038},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-10-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-14","defaultRemindTime":1763130600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-14","currency":"USD","dateTimestamp":1763096400000,"payDate":"2025-11-28"},{"market":"US","date":"2025-10-29","symbol":"PFS","fiscalQuarterEnding":"2025/09","expectedEps":0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761710400000,"reportTimeType":"post","actualEps":0.55},{"date":"2025-08-15","symbol":"PFS","amount":0.24,"announcedDate":"2025-07-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-15","defaultRemindTime":1755264600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-15","currency":"USD","dateTimestamp":1755230400000,"payDate":"2025-08-29"},{"market":"US","date":"2025-07-24","symbol":"PFS","fiscalQuarterEnding":"2025/06","expectedEps":0.5,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753329600000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"},{"executeDate":"2016-11-10","recordDate":"2016-11-15","paymentDate":"2016-11-30","value":0.18,"currency":"USD"},{"executeDate":"2017-02-13","recordDate":"2017-02-15","paymentDate":"2017-02-28","value":0.19,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1750914000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-12-16","current":10.626337,"percent":0.492382,"low":6.410614,"twenty":8.984755,"median":10.767655,"eighty":16.928687,"high":33.979783,"avg":13.414611,"sd":6.411419,"marketCap":2749601183},"quantilePoints":[{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-18","current":16.4974,"twenty":8.954399,"median":10.718159,"eighty":16.928687,"marketCap":2432888120},{"date":"2025-07-25","current":10.379214,"twenty":8.954399,"median":10.725223,"eighty":16.928687,"marketCap":2396954859},{"date":"2025-08-01","current":10.305683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2379973707},{"date":"2025-08-08","current":10.124683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2338173949},{"date":"2025-08-15","current":10.899581,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2517127428},{"date":"2025-08-22","current":10.633738,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2455734076},{"date":"2025-08-29","current":11.255924,"twenty":8.954399,"median":10.756738,"eighty":16.928687,"marketCap":2599420644},{"date":"2025-09-05","current":11.380362,"twenty":8.954068,"median":10.786944,"eighty":16.930946,"marketCap":2628157958},{"date":"2025-09-12","current":11.312487,"twenty":8.954399,"median":10.806309,"eighty":16.928687,"marketCap":2612483060},{"date":"2025-09-19","current":11.493487,"twenty":8.954399,"median":10.823106,"eighty":16.928687,"marketCap":2654282788},{"date":"2025-09-26","current":11.0523,"twenty":8.984755,"median":10.848771,"eighty":16.928687,"marketCap":2552395949},{"date":"2025-10-03","current":11.018362,"twenty":8.984755,"median":10.865282,"eighty":16.928687,"marketCap":2544558500},{"date":"2025-10-10","current":10.876956,"twenty":8.984755,"median":10.902195,"eighty":16.928687,"marketCap":2511902462},{"date":"2025-10-17","current":10.113363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2335559855},{"date":"2025-10-24","current":10.475363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2419159313},{"date":"2025-10-31","current":9.425046,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2415196286},{"date":"2025-11-07","current":9.328196,"twenty":8.984755,"median":10.888266,"eighty":16.928687,"marketCap":2390378153},{"date":"2025-11-14","current":9.557624,"twenty":8.984755,"median":10.857,"eighty":16.928687,"marketCap":2449169700},{"date":"2025-11-21","current":9.205903,"twenty":8.984755,"median":10.840069,"eighty":16.928687,"marketCap":2359040255},{"date":"2025-11-28","current":9.812493,"twenty":8.984755,"median":10.820894,"eighty":16.928687,"marketCap":2514480892},{"date":"2025-12-05","current":10.210091,"twenty":8.984755,"median":10.806309,"eighty":16.928687,"marketCap":2616366351},{"date":"2025-12-12","current":10.628077,"twenty":8.984755,"median":10.780942,"eighty":16.928687,"marketCap":2723476706},{"date":"2025-12-16","current":10.730025,"twenty":8.984755,"median":10.767655,"eighty":16.928687,"marketCap":2749601183}],"updateTime":1765971972510},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592948879","title":"3 Dividend Stocks To Enhance Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592948879","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592948879?lang=en_us&edition=fundamental","pubTime":"2025-12-18 01:02","pubTimestamp":1765990926,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a period of volatility with major indices like the S&P 500 and Dow Jones experiencing consecutive losses, investors are increasingly seeking stable returns amidst concerns over tech sector declines and AI bubble fears. In such an environment, dividend stocks can offer a reliable income stream, providing investors with potential stability and growth opportunities even when market conditions are challenging.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nasdaq-nbtb/nbt-bancorp/news/3-dividend-stocks-to-enhance-your-portfolio-6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nasdaq-nbtb/nbt-bancorp/news/3-dividend-stocks-to-enhance-your-portfolio-6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FIBK","BK4112","PFS","LU1559883803.SGD","PEBO","BK4211","BK4195","DDS","WABC","BK4220","FMNB","LU0566484027.USD","EBF","BK4103","NBTB","COLB","PCB","CZNC","BK4087","OTCM"],"gpt_icon":0},{"id":"2592990158","title":"Provident Financial Services Inc. Appoints New Executives and Promotes Key Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990158","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990158?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976504,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc. has announced key management changes, including the promotion of Satish Harikrishnan to Senior Vice President, Chief Technology Officer, and the appointment of Shyam Nair as Senior Vice President, Head of Data, Analytics, and Data Governance. The company also promoted Linda Martin to lead the Central Region. These changes are part of Provident Bank's ongoing growth and expansion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provident Financial Services Inc. published the original content used to generate this news brief via GlobeNewswire  on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL6kMcQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4195","BK4588","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4211","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","LU0314104364.USD","SG9999014005.SGD","PFS","NDAQ","BK4585","SG9999014021.USD"],"gpt_icon":0},{"id":"2592902990","title":"Press Release: Provident Bank Announces New Hires and Promotions","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Dec. 17, 2025  -- Provident Bank, a leading New Jersey-based financial institution, has announced the appointment of two executives and the promotion of two leaders, rounding out a year of growth and expansion. These latest strategic new hires and promotions further underscore Provident's commitment to sustainable growth, continued investment in technology, an exceptional customer experience, and meaningful community impact. Below are details on each executive and their role within Provident.Satish Harikrishnan has been promoted to Senior Vice President, Chief Technology Officer.In this role, Mr. Harikrishnan is responsible for setting and executing the bank's technology strategy to support business growth, operational efficiency, cybersecurity, and regulatory compliance. In addition, he will oversee enterprise technology platforms, infrastructure, application development, data capabilities, and vendor relationships while ensuring systems are secure, resilient, and aligne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PFS","BK4195"],"gpt_icon":0},{"id":"2592199259","title":"Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199259","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592199259?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972800,"startTime":"0","endTime":"0","summary":"Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206840/0/en/Faridoxorubicin-AVA6000-Phase-1b-cohort-demonstrates-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","SGC","BK4211","BK4202","PFS"],"gpt_icon":0},{"id":"1131509857","title":"Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1131509857","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131509857?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:20","pubTimestamp":1765956051,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (referred to as \"Junshi Biosciences\") recently submitted its prospectus to the Hong Kong Stock Exchange. The company, a biotech firm focused on innovative cell...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","PFS","BK4585","BK4139","LU2487616109.SGD","ORR","BK4211","BK4505","BK4195","L","LU0053666078.USD","BK4107","LU0210528500.USD","BK4588"],"gpt_icon":0},{"id":"1110626945","title":"FDA Approves Enhertu Combination Therapy for First-Line HER2-Positive Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1110626945","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110626945?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:50","pubTimestamp":1765900218,"startTime":"0","endTime":"0","summary":"The U.S. FDA has approved AstraZeneca PLC (AZN) and Daiichi Sankyo's (TYO: 4568) fam-trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for first-line treatment of HER2-positive breast...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","PFS","BK4588","BK4007","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","BK4211","LU2236285917.USD","BK4585","BK4568","LU2417539215.USD","LU1829250122.USD","LU2462157665.USD","AZN","BK4195"],"gpt_icon":0},{"id":"2591262060","title":"Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591262060","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591262060?lang=en_us&edition=fundamental","pubTime":"2025-12-16 03:24","pubTimestamp":1765826696,"startTime":"0","endTime":"0","summary":"Celcuity Inc. recently reported updated Phase 3 VIKTORIA-1 results for its PAM inhibitor gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer, highlighting substantial progression-free survival benefits over fulvestrant in multiple patient sub-groups and geographies.\nAn interesting feature of the data is the combination of extended progression-free survival with stable glucose levels and manageable stomatitis, underscoring a differentiated tolerability profile versus many...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/did-gedatolisibs-phase-3-pfs-and-tolerability-data-just-shif","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/did-gedatolisibs-phase-3-pfs-and-tolerability-data-just-shif","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PFS","BK4211","BK4139","BK4195","CELC"],"gpt_icon":0},{"id":"2590503323","title":"Dividend Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503323?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:01","pubTimestamp":1765537299,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are eyeing opportunities in dividend stocks that can offer steady income amidst fluctuating market conditions. A good dividend stock typically combines strong fundamentals with a reliable payout history, making it an attractive option for those looking to balance growth potential with income stability in today's dynamic economic landscape.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nyse-rf/regions-financial/news/dividend-stocks-to-consider-in-december-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nyse-rf/regions-financial/news/dividend-stocks-to-consider-in-december-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FMNB","PFS","CVBF","OTCM","LU1559883803.SGD","BK4087","CZNC","LU1880398471.USD","BK4588","FIBK","PEBO","BK4195","PCB","EBF","BK4181","BK4211","COLB","RF","LU1880398554.USD","BK4585","BK4112","LU0566484027.USD","UBSI","HST","BK4218","LU1883839398.USD"],"gpt_icon":0},{"id":"2590597165","title":"InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597165","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597165?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:03","pubTimestamp":1765450980,"startTime":"0","endTime":"0","summary":"BEIJING, Dec.  11, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (IC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","PFS","OS","ORR","BK4211","BK4097","BK4195","NGS"],"gpt_icon":0},{"id":"2590530117","title":"High-Grade Sandstone Hub Drilling And PFS Progress Could Be A Game Changer For Brightstar Resources (ASX:BTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590530117","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590530117?lang=en_us&edition=fundamental","pubTime":"2025-12-10 23:18","pubTimestamp":1765379930,"startTime":"0","endTime":"0","summary":"Brightstar Resources has reported outstanding high-grade gold drilling results at its Sandstone Hub in Western Australia, including standout intercepts at the Bull Oak and Havilah deposits, while also confirming the past resignation of Non-Executive Director Ashley Fraser effective 2 December 2025.\nBy running six drill rigs and feeding new data into an updated Pre-Feasibility Study due in 2026, Brightstar is sharpening its understanding of Sandstone Hub’s economic potential and its role as a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-btr/brightstar-resources-shares/news/high-grade-sandstone-hub-drilling-and-pfs-progress-could-be","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-btr/brightstar-resources-shares/news/high-grade-sandstone-hub-drilling-and-pfs-progress-could-be","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HUBG","BK7506","IE0031619046.USD","PFS","PRGS","BK4195","BK4097","IE00B66KJ199.SGD","LU2065732104.USD","BK4131","BK4211","BTR","BK7104","IE00B7SZL793.SGD","BTR.AU","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2590456673","title":"1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456673?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:15","pubTimestamp":1765282500,"startTime":"0","endTime":"0","summary":"Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","LU2413666699.HKD","LU2413666426.HKD","LU2092937221.SGD","BK4097","FUL","PFS","DDFS","BK4121","BK4588","IE00BN0W2T93.GBP","OS","BK4567","LU1165135440.EUR","EBC","LU0347712357.USD","BK4590","BK4144","BK4561","BK4211","A","LU2229751404.USD","BK4581","LU1721428933.USD","ET","LU2089279066.USD","IE00BN0W2V16.EUR","BK4109","BK4195","LU1543694498.USD","LU2041044095.USD"],"gpt_icon":0},{"id":"2590318860","title":"Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318860","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318860?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:00","pubTimestamp":1765263600,"startTime":"0","endTime":"0","summary":"Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and tar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202069/0/en/Scancell-updated-Phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iSCIB1-in-patients-with-first-line-advanced-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0690374961.EUR","PFS","GB00B4LPDJ14.GBP","LU2404859741.USD","IE00BD0PCF45.HKD","BK4195","IE00B0T0GQ85.USD","IE00B1G9WX41.USD","IE00B95QR487.USD","BK4211","BK4585","LU2404859667.USD","BK4588","LU1718418525.SGD","BK4097","GB00B4QBRK32.GBP","BK4142","IE00B45NX917.SGD","MAR","LU0690374615.EUR","OS","BK4156"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE0031619046.USD","LU0963586101.USD","LU2065731478.USD","PFS","BK4109","BK4161","CR","BK4187","ASH","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4006","CRS","OS","ORR","LU2463526074.USD","BK4097","BK4211"],"gpt_icon":0},{"id":"2590368866","title":"Why Is Arcellx Stock Surging Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368866","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368866?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:23","pubTimestamp":1765218180,"startTime":"0","endTime":"0","summary":"Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1430594728.SGD","IE00B7SZLL34.SGD","BK4139","BK4550","SG9999015945.SGD","BK4532","IE00B19Z3581.USD","BK4566","BK4588","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","PFS","BK4195","BK4583","LU1674673428.USD","SG9999015986.USD","GILD","LU0882574055.USD","BK4109","OS","IE00B19Z3B42.SGD","LU1571399168.USD","ASH","BK4211","LU2463526074.USD","LU1585245621.USD","LU0889565916.HKD","LU1839511570.USD","SG9999015952.SGD","LU0109394709.USD","BK4578","LU2087621335.USD","LU2089984988.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0114720955.EUR","LU0823416689.USD","LU1674673691.USD","ACLX","ORR","BK4097","LU1778281490.HKD","LU0234570918.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU1066053197.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2589354927","title":"Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354927?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","OS","CRVS","LU2463526074.USD","BK4211","BK4097","PFS","ASH","BK4109","BK4195"],"gpt_icon":0},{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU0912757837.SGD","LU2592432038.USD","LU0203347892.USD","LU1929549753.HKD","BK4504","IE00B19Z3B42.SGD","LU0058720904.USD","IE00BJT1NW94.SGD","LU0466842654.USD","ORR.AU","LU0345769631.USD","OS","BK4585","LU0234572021.USD","LU1894683348.USD","LU0345770308.USD","BK4581","LU1261432733.SGD","LU2089984988.USD","IE00B19Z3581.USD","LU2602419157.SGD","IE00B1BXHZ80.USD","LU1267930813.SGD","JNJ","IE00BLSP4452.SGD","SEER","LU2468319806.SGD","LU2129689514.USD","PFS","LU0345770993.USD","LU1732799900.SGD","LU1162221912.USD","IE00B4R5TH58.HKD","LU1674673691.USD","BK7095","LU2505996509.AUD","BK4195","BK4534","IE00B3T34201.USD","BK4550","LU0098860793.USD","LU1066051225.USD","LU1074936037.SGD","LU2505996681.GBP","IE00B3PB1722.GBP","IE00BGHQF631.EUR","ORR","LU1778281490.HKD","BK4559"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4109","BK4124","BK4211","ALX","ASH","OS","BK4161","CR","BK4195","SMP","BK4097","BK4080","BK4213","LU2463526074.USD","PFS","ORR","PR"],"gpt_icon":0},{"id":"2589187279","title":"Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589187279","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589187279?lang=en_us&edition=fundamental","pubTime":"2025-12-07 20:50","pubTimestamp":1765111800,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201123/0/en/Genmab-Presents-Pivotal-Phase-3-Data-from-EPCORE-FL-1-Trial-Demonstrating-Clinical-Benefit-of-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-R2-in-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","ASH","BK4161","BK4195","LU2463526074.USD","ORR","PFS","CR","BK4109"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","ASH","BK4226","BK4161","LU0545562505.USD","CRS","BK4548","BK4106","BK4109","BK4187","BR","IPI","BK4097","LU2463526074.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4006","BK4093","IE0031619046.USD","BK4588","LU0390134368.USD","LU1228905540.USD","BK4211","BK4195","LU0963586101.USD","ORR","OS","IE0034235188.USD","PFS","IE0009354923.USD","CR","IE00B19Z4B17.USD","BK4585"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","GP","AEIS","IE0031619046.USD","BK4006","BK4195","IE00B19Z4B17.USD","LU0054578231.USD","BK4149","LU1815336091.USD","BK4097","BK4211","LU0757428866.USD","LU0053671581.USD","IE00B7SZL793.SGD","BK4157","HCC","ITT","OS","RCC","IE00B66KJ199.SGD","PFS","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":185,"code":"91000000","status":"200"}]}}